Why the study?
Are there sex-specific differences in the efficacy and safety of acute coronary syndrome management strategies between women and men?
Are there sex-specific differences in the efficacy and safety of acute coronary syndrome management strategies between women and men?
This review highlights the need for female-specific therapeutic strategies in ACS, noting that while women benefit similarly from many standard therapies, they face higher bleeding risks and potential differences in response to certain antiplatelet and fibrinolytic agents.
Answers are grounded in this paper and cite their sources.
Women with ACS need bleeding-risk mitigation alongside standard therapies; leaves open need for sex-specific trials on fibrinolytics and GP IIb/IIIa inhibitors.
Coronary heart disease (CHD) is the leading cause of morbidity and mortality in both men and women in the developed countries. Despite this fact, females are still under-represented in the majority of clinical trials. At the present time, only limited evidence is available with respect to the female-specific aspects of pathogenesis, management, and outcomes in acute coronary syndrome (ACS). Women less frequently undergo coronary intervention, and a lower proportion of women receive evidence-based pharmacotherapy, compared with men. It has been shown that women benefit from an invasive approach and coronary intervention in ACS as much as men, despite their advanced age and higher rate of bleeding complications. Also, administration of beta-blockers, ACE-inhibitors, and intensive statin therapy is associated with a comparable reduction of cardiovascular event rates in women and men. On the other hand, women may profit less than men from fibrinolytic or glycoprotein IIb/IIIa inhibitor therapy. Both sexes benefit equally from aspirin therapy, whereas contradictory data are available on the efficacy of clopidogrel in women. There is an urgent need for intensive research in the development of female-specific therapeutic strategy in ACS, even though the detailed mechanisms of sex differences are still unknown.
No takes yet. Share an insight, caveat, or question.
Petr Ošťádal (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: